Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 420 articles:
HTML format



Single Articles


    December 2022
  1. AIHARA T, Kumamaru H, Ishitobi M, Miyashita M, et al
    Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
    Breast Cancer Res Treat. 2022;196:635-645.
    PubMed     Abstract available


  2. WILLIAMS AD, Pawloski KR, Wen HY, Sevilimedu V, et al
    Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.
    Breast Cancer Res Treat. 2022;196:565-570.
    PubMed     Abstract available


  3. SHAFI S, Hu Y, Parwani AV, Ding Q, et al
    Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
    Breast Cancer Res Treat. 2022;196:463-469.
    PubMed     Abstract available


  4. CHA E, Ambinder EB, Oluyemi ET, Mullen LA, et al
    High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy.
    Breast Cancer Res Treat. 2022;196:517-525.
    PubMed     Abstract available


  5. GUZZO HM, Valente SA, Schwarz GS, ElSherif A, et al
    Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction.
    Breast Cancer Res Treat. 2022;196:657-664.
    PubMed     Abstract available


  6. CASAUBON J, Niakan S, Vicks E, Perez Coulter A, et al
    The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar.
    Breast Cancer Res Treat. 2022;196:527-534.
    PubMed     Abstract available


    November 2022
  7. HABBOUS S, Barisic A, Homenauth E, Kandasamy S, et al
    Estimating the incidence of breast cancer recurrence using administrative data.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06812.
    PubMed     Abstract available


  8. D'CUNHA K, Park Y, Protani MM, Reeves MM, et al
    Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06792.
    PubMed     Abstract available


  9. AHN JH, Park JM, Choi SB, Go J, et al
    Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Nov 23. doi: 10.1007/s10549-022-06760.
    PubMed     Abstract available


  10. ALJOHANI AI, Toss MS, Green AR, Rakha EA, et al
    The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.
    Breast Cancer Res Treat. 2022 Nov 22. doi: 10.1007/s10549-022-06801.
    PubMed     Abstract available


  11. ACEVEDO F, Walbaum B, Medina L, Merino T, et al
    Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06814.
    PubMed     Abstract available


  12. KAWAI M, Takada M, Nakayama T, Masuda N, et al
    Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06816.
    PubMed     Abstract available


  13. BURNETTE SE, Poehlein E, Lee HJ, Force J, et al
    Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06798.
    PubMed     Abstract available


  14. WANG H, Sheng X, Yan T, Xu Y, et al
    Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 Nov 21. doi: 10.1007/s10549-022-06791.
    PubMed     Abstract available


  15. NOTEWARE L, Broadwater G, Dalal N, Alder L, et al
    Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
    Breast Cancer Res Treat. 2022 Nov 20. doi: 10.1007/s10549-022-06799.
    PubMed     Abstract available


  16. NUSSBAUMER RL, Maggi N, Castrezana L, Zehnpfennig L, et al
    The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery.
    Breast Cancer Res Treat. 2022 Nov 20. doi: 10.1007/s10549-022-06811.
    PubMed     Abstract available


  17. BARDIA A, Mayer I, Winer E, Linden HM, et al
    The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Nov 19. doi: 10.1007/s10549-022-06797.
    PubMed     Abstract available


  18. BERGMAN R, Berko YA, Sanchez V, Sanders ME, et al
    Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.
    Breast Cancer Res Treat. 2022 Nov 17. pii: 10.1007/s10549-022-06794.
    PubMed     Abstract available


  19. GLYNN D, Bliss J, Brunt AM, Coles CE, et al
    Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
    Breast Cancer Res Treat. 2022 Nov 17. pii: 10.1007/s10549-022-06802.
    PubMed     Abstract available


  20. YAZAKI S, Shimoi T, Yoshida M, Sumiyoshi-Okuma H, et al
    Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Nov 16. pii: 10.1007/s10549-022-06787.
    PubMed     Abstract available


  21. LACOURT TE, Koncz Z, Tullos EA, Tripathy D, et al
    A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Nov 16. pii: 10.1007/s10549-022-06805.
    PubMed     Abstract available


  22. LI J, Sun B, Li Y, Li S, et al
    Correlation analysis between shear-wave elastography and pathological profiles in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 14. pii: 10.1007/s10549-022-06804.
    PubMed     Abstract available


  23. JOYCE E, Carr G, Wang S, Brummett CM, et al
    Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients.
    Breast Cancer Res Treat. 2022 Nov 13. pii: 10.1007/s10549-022-06806.
    PubMed     Abstract available


  24. YANG Z, Xu H, Yang Y, Duan C, et al
    Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis.
    Breast Cancer Res Treat. 2022 Nov 12. pii: 10.1007/s10549-022-06790.
    PubMed     Abstract available


  25. NEUNER JM, Fergestrom N, Pezzin LE, Laud PW, et al
    Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 10. pii: 10.1007/s10549-022-06704.
    PubMed     Abstract available


  26. WALPOLE ET, Youl PH, Moore J, Morris M, et al
    Development of a key performance indicator for breast cancer in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Nov 9. pii: 10.1007/s10549-022-06796.
    PubMed     Abstract available


  27. BHATTACHARYA M, Parsons H, Call K, Blaes A, et al
    Impact of a pre-existing diagnosis of mental illness on stage of breast cancer diagnosis among older women.
    Breast Cancer Res Treat. 2022 Nov 9. pii: 10.1007/s10549-022-06793.
    PubMed     Abstract available


  28. CHEN R, Qi Y, Huang Y, Liu W, et al
    Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
    Breast Cancer Res Treat. 2022 Nov 8. pii: 10.1007/s10549-022-06781.
    PubMed     Abstract available


  29. LE MK, Odate T, Kawai M, Oishi N, et al
    Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study.
    Breast Cancer Res Treat. 2022 Nov 6. pii: 10.1007/s10549-022-06768.
    PubMed     Abstract available


  30. PLICHTA JK, Rushing CN, Lewis HC, Rooney MM, et al
    Implications of missing data on reported breast cancer mortality.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06764.
    PubMed     Abstract available


  31. LU C, Yang Y, Lingmei L, Qiujuan H, et al
    Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06788.
    PubMed     Abstract available


  32. EIJKELBOOM AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, et al
    Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
    Breast Cancer Res Treat. 2022 Nov 5. pii: 10.1007/s10549-022-06732.
    PubMed     Abstract available


  33. POWELL M, Fuller S, Gunderson E, Benz C, et al
    A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
    Breast Cancer Res Treat. 2022 Nov 4. pii: 10.1007/s10549-022-06789.
    PubMed     Abstract available


  34. CORSO G, Girardi A, Calvello M, Gandini S, et al
    Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
    Breast Cancer Res Treat. 2022 Nov 4. pii: 10.1007/s10549-022-06776.
    PubMed     Abstract available


  35. HUPPERT LA, Walker Z, Li M, Kim MO, et al
    Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study.
    Breast Cancer Res Treat. 2022 Nov 2. pii: 10.1007/s10549-022-06771.
    PubMed     Abstract available


  36. LEVY J, Farag F, Cole J
    Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.
    Breast Cancer Res Treat. 2022;196:207-213.
    PubMed     Abstract available


  37. GAO W, Lu S, Zeng Y, Chen X, et al
    Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.
    Breast Cancer Res Treat. 2022;196:129-141.
    PubMed     Abstract available


  38. HASSING CMS, Mejdahl MK, Laenkholm AV, Kroman N, et al
    Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors
    Breast Cancer Res Treat. 2022;196:197-206.
    PubMed     Abstract available


  39. QU FL, Lin CJ, Liu ZB, Cao AY, et al
    Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
    Breast Cancer Res Treat. 2022;196:97-109.
    PubMed     Abstract available


  40. LOSURDO A, Lisa AVE, Tomatis M, Ponti A, et al
    Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience.
    Breast Cancer Res Treat. 2022;196:87-95.
    PubMed     Abstract available


  41. NICOSIA L, Lissidini G, Sargenti M, Bozzini AC, et al
    Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center.
    Breast Cancer Res Treat. 2022;196:371-377.
    PubMed     Abstract available


  42. LAITMAN Y, Nielsen SM, Bernstein-Molho R, Heald B, et al
    Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
    Breast Cancer Res Treat. 2022;196:355-361.
    PubMed     Abstract available


  43. POTTER S, Fairhurst K, Cowan K, Vincent S, et al
    Identifying research priorities in breast cancer surgery: a UK priority setting partnership with the James Lind Alliance.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06756.
    PubMed     Abstract available


  44. SUBHAM S, Jeppson JD, Worcester C, Schatmeyer B, et al
    EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06783.
    PubMed     Abstract available


  45. GUPTA T, Vinayak S, Telli M
    Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Nov 1. pii: 10.1007/s10549-022-06780.
    PubMed     Abstract available


    October 2022
  46. EIJKELBOOM AH, de Munck L, de Vries M, Francken AB, et al
    Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis.
    Breast Cancer Res Treat. 2022 Oct 31. pii: 10.1007/s10549-022-06757.
    PubMed     Abstract available


  47. XIE XF, Zhang QY, Huang JY, Chen LP, et al
    Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
    Breast Cancer Res Treat. 2022 Oct 30. pii: 10.1007/s10549-022-06770.
    PubMed     Abstract available


  48. GHAZALEH AA, Handschin TM, Buckowiecki J, Chammartin FS, et al
    Combining reconstructive and ablative surgical treatment of chronic breast cancer-related lymphedema (BCRL): safe and effective.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06778.
    PubMed     Abstract available


  49. LIM GH, Alcantara VS, Ng RP, Ng R, et al
    Patterns of breast cancer second recurrences in patients after mastectomy.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06772.
    PubMed     Abstract available


  50. BURCH AE, Irish WD, Wong JH
    A population health assessment of screening mammography on breast cancer mortality in North Carolina.
    Breast Cancer Res Treat. 2022 Oct 26. pii: 10.1007/s10549-022-06773.
    PubMed     Abstract available


  51. LOBANOVA O, Medvedieva N, Fishchuk L, Dubitska O, et al
    Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06774.
    PubMed     Abstract available


  52. DESALEGN Z, Yohannes M, Porsch M, Stuckrath K, et al
    Intrinsic subtypes in Ethiopian breast cancer patient.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06769.
    PubMed     Abstract available


  53. POHLMANN PR, Graham D, Wu T, Ottaviano Y, et al
    HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
    Breast Cancer Res Treat. 2022 Oct 25. pii: 10.1007/s10549-022-06743.
    PubMed     Abstract available


  54. REINHARDT K, Stuckrath K, Hartung C, Kaufhold S, et al
    PIK3CA-mutations in breast cancer.
    Breast Cancer Res Treat. 2022 Oct 24. pii: 10.1007/s10549-022-06637.
    PubMed     Abstract available


  55. LIANG Z, Bian X, Shim H
    Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression.
    Breast Cancer Res Treat. 2022 Oct 23. pii: 10.1007/s10549-022-06779.
    PubMed    


  56. TOOHEY K, Hunter M, McKinnon K, Casey T, et al
    systematic review of multimodal prehabilitation in breast cancer.
    Breast Cancer Res Treat. 2022 Oct 21. pii: 10.1007/s10549-022-06759.
    PubMed     Abstract available


  57. VIHERVUORI H, Korpinen K, Autere TA, Repo H, et al
    Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.
    Breast Cancer Res Treat. 2022 Oct 19. pii: 10.1007/s10549-022-06767.
    PubMed     Abstract available


  58. FREEDMAN RA, Ko NY, Lederman RI, Gagnon H, et al
    Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors.
    Breast Cancer Res Treat. 2022 Oct 11. pii: 10.1007/s10549-022-06752.
    PubMed     Abstract available


  59. MORENO GA, Molina MI, Eastwood D, Auer PL, et al
    Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06754.
    PubMed     Abstract available


  60. BROWN L, Naffouje SA, Sam C, Laronga C, et al
    Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06751.
    PubMed     Abstract available


  61. ZHENG Q, Luo H, Xia W, Lu Q, et al
    Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
    Breast Cancer Res Treat. 2022 Oct 7. pii: 10.1007/s10549-022-06746.
    PubMed     Abstract available


  62. LAW JW, Campbell A, Weller C, Johanson C, et al
    Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.
    Breast Cancer Res Treat. 2022 Oct 6. pii: 10.1007/s10549-022-06738.
    PubMed     Abstract available


  63. LOESER AL, Gao L, Bardia A, Burkard ME, et al
    Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
    Breast Cancer Res Treat. 2022 Oct 6. pii: 10.1007/s10549-022-06755.
    PubMed     Abstract available


  64. VERMA N, Blackford AL, Thorner E, Lehman J, et al
    Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Oct 5. pii: 10.1007/s10549-022-06750.
    PubMed     Abstract available


  65. STANKOWSKI TJ, Schumacher JR, Hanlon BM, Tucholka JL, et al
    Barriers to breast reconstruction for socioeconomically disadvantaged women.
    Breast Cancer Res Treat. 2022;195:413-419.
    PubMed     Abstract available


  66. JOBSEN JJ, Struikmans H, Siemerink E, van der Palen J, et al
    The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.
    Breast Cancer Res Treat. 2022;195:249-262.
    PubMed     Abstract available


  67. RASK G, Nazemroaya A, Jansson M, Wadsten C, et al
    Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.
    Breast Cancer Res Treat. 2022;195:367-377.
    PubMed     Abstract available


  68. VAN OMMEN-NIJHOF A, Jacobse JN, Steggink LC, Lefrandt JD, et al
    Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Oct 1. pii: 10.1007/s10549-022-06714.
    PubMed     Abstract available


    September 2022
  69. PAN B, Xu Y, Zhou Y, Yao R, et al
    Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017).
    Breast Cancer Res Treat. 2022 Sep 27. pii: 10.1007/s10549-022-06747.
    PubMed     Abstract available


  70. JIMBO H, Horimoto Y, Ishizuka Y, Nogami N, et al
    Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Sep 26. pii: 10.1007/s10549-022-06748.
    PubMed     Abstract available


  71. INOUE Y, Fujishima M, Ono M, Masuda J, et al
    Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
    Breast Cancer Res Treat. 2022 Sep 24. pii: 10.1007/s10549-022-06726.
    PubMed     Abstract available


  72. OPPONG BA, Rolle AA, Ndumele A, Li Y, et al
    Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?
    Breast Cancer Res Treat. 2022 Sep 24. pii: 10.1007/s10549-022-06736.
    PubMed     Abstract available


  73. MAN V, Luk WP, Fung LH, Kwong A, et al
    The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Sep 22. pii: 10.1007/s10549-022-06699.
    PubMed     Abstract available


  74. MCCARTHY AM, Manning AK, Hsu S, Welch M, et al
    Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer.
    Breast Cancer Res Treat. 2022 Sep 22. pii: 10.1007/s10549-022-06739.
    PubMed     Abstract available


  75. HEEKE AL, Elliott A, Feldman R, O'Connor HF, et al
    Molecular characterization of ESR1 variants in breast cancer.
    Breast Cancer Res Treat. 2022 Sep 20. pii: 10.1007/s10549-022-06740.
    PubMed     Abstract available


  76. CHITKARA A, Mesa-Eguiagaray I, Wild SH, Hall PS, et al
    Reproductive history differs by molecular subtypes of breast cancer among women aged
    Breast Cancer Res Treat. 2022 Sep 18. pii: 10.1007/s10549-022-06721.
    PubMed     Abstract available


  77. ALEIXO GFP, Valente SA, Wei W, Moore HCF, et al
    Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06741.
    PubMed     Abstract available


  78. PEZO RC, Chan KKW, Mata DGMM, Menjak I, et al
    Impact of body mass index on survival in women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06744.
    PubMed     Abstract available


  79. ALVAREZ FA, Kaddour H, Lyu Y, Preece C, et al
    Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment.
    Breast Cancer Res Treat. 2022 Sep 17. pii: 10.1007/s10549-022-06733.
    PubMed     Abstract available


  80. WILSON JM, Colebaugh CA, Flowers KM, Edwards RR, et al
    Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 14. pii: 10.1007/s10549-022-06720.
    PubMed     Abstract available


  81. CHEN M, Li S, Huang M, Guo J, et al
    Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Sep 13. pii: 10.1007/s10549-022-06707.
    PubMed     Abstract available


  82. THILL M, Wimberger P, Grafe A, Klare P, et al
    Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
    Breast Cancer Res Treat. 2022 Sep 12. pii: 10.1007/s10549-022-06710.
    PubMed     Abstract available


  83. ALTUNDAG K
    Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06742.
    PubMed    


  84. SMITH CEP, Marcom PK, Mitri Z, Ko NY, et al
    Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06718.
    PubMed     Abstract available


  85. WATANABE H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06731.
    PubMed     Abstract available


  86. GREMKE N, Griewing S, Kalder M, Kostev K, et al
    Positive association between body height and breast cancer prevalence: a retrospective study with 135,741 women in Germany.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06730.
    PubMed     Abstract available


  87. GUNDA A, Eshwaraiah MS, Gangappa K, Kaur T, et al
    A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06729.
    PubMed     Abstract available


  88. NGUYEN THN, Nguyen TTN, Nguyen TTM, Nguyen LHM, et al
    Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06728.
    PubMed     Abstract available


  89. SWARNKAR P, Mokbel L, Mokbel K
    De-escalation of breast cancer treatment for Her2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06737.
    PubMed    


  90. SAJDIK C, Schuster E, Holzer B, Krainer M, et al
    Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 8. pii: 10.1007/s10549-022-06717.
    PubMed     Abstract available


  91. PARK SY, Suh KJ, Lee DW, Ryu HS, et al
    Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.
    Breast Cancer Res Treat. 2022 Sep 7. pii: 10.1007/s10549-022-06566.
    PubMed     Abstract available


  92. XIE W, Cao M, Zhong Z, Huang Z, et al
    Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer.
    Breast Cancer Res Treat. 2022 Sep 7. pii: 10.1007/s10549-022-06725.
    PubMed     Abstract available


  93. HOWARD FM, He G, Peterson JR, Pfeiffer JR, et al
    Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.
    Breast Cancer Res Treat. 2022 Sep 5. pii: 10.1007/s10549-022-06722.
    PubMed     Abstract available


  94. SONG YM, Qian XL, Xia XQ, Li YQ, et al
    STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Breast Cancer Res Treat. 2022 Sep 3. pii: 10.1007/s10549-022-06679.
    PubMed     Abstract available


  95. SANLI AN, Altundag K
    Strict definition of a small tumor in breast cancer should be revisited.
    Breast Cancer Res Treat. 2022 Sep 2. pii: 10.1007/s10549-022-06734.
    PubMed    


  96. WEISS A, King C, Vincuilla J, Parker T, et al
    Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022;195:181-189.
    PubMed     Abstract available


  97. LINFIELD DT, Rothberg MB, Pfoh ER, Noss R, et al
    Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    Breast Cancer Res Treat. 2022;195:153-160.
    PubMed     Abstract available


    August 2022
  98. CHOONG GM, Liddell S, Ferre RAL, O'Sullivan CC, et al
    Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06713.
    PubMed     Abstract available


  99. KWON SS, Nam BD, Lee MY, Lee MH, et al
    Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06696.
    PubMed     Abstract available


  100. MUNGMUNPUNTIPANJTIP R, Sriwijitalai W, Wiwanitkit V
    Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence.
    Breast Cancer Res Treat. 2022 Aug 31. pii: 10.1007/s10549-022-06719.
    PubMed    


  101. SU Y, Wu C, Chang Y, Li L, et al
    USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells.
    Breast Cancer Res Treat. 2022 Aug 30. pii: 10.1007/s10549-022-06711.
    PubMed     Abstract available


  102. KLINTMAN M, Rosendahl AH, Randeris B, Eriksson M, et al
    Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.
    Breast Cancer Res Treat. 2022 Aug 30. pii: 10.1007/s10549-022-06664.
    PubMed     Abstract available


  103. GUPTA T, Purington N, Liu M, Han S, et al
    Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Breast Cancer Res Treat. 2022 Aug 28. pii: 10.1007/s10549-022-06716.
    PubMed     Abstract available


  104. FERRAIUOLO RM, Fifield BA, Hamm C, Porter LA, et al
    Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.
    Breast Cancer Res Treat. 2022 Aug 27. pii: 10.1007/s10549-022-06715.
    PubMed     Abstract available


  105. ROZENBLIT M, Blenman K, Harigopal M, Reisenbichler E, et al
    PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.
    Breast Cancer Res Treat. 2022 Aug 26. pii: 10.1007/s10549-022-06712.
    PubMed     Abstract available


  106. WHITAKER KD, Wang X, Ascha M, Showalter TN, et al
    Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Aug 26. pii: 10.1007/s10549-022-06701.
    PubMed     Abstract available


  107. FILE DM, Pascual T, Deal AM, Wheless A, et al
    Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Aug 25. pii: 10.1007/s10549-022-06700.
    PubMed     Abstract available


  108. NEMATI SHAFAEE M, Goutsouliak K, Lin H, Bevers TB, et al
    Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
    Breast Cancer Res Treat. 2022 Aug 25. pii: 10.1007/s10549-022-06688.
    PubMed     Abstract available


  109. WALSH EM, Gucalp A, Patil S, Edelweiss M, et al
    Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
    Breast Cancer Res Treat. 2022 Aug 20. pii: 10.1007/s10549-022-06669.
    PubMed     Abstract available


  110. MURALI B, Durbin L, Vijaykumar S, Yang L, et al
    Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019.
    Breast Cancer Res Treat. 2022 Aug 20. pii: 10.1007/s10549-022-06709.
    PubMed     Abstract available


  111. KUILMAN MM, Ellappalayam A, Barcaru A, Haan JC, et al
    BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
    Breast Cancer Res Treat. 2022 Aug 19. pii: 10.1007/s10549-022-06698.
    PubMed     Abstract available


  112. CUNNINGHAM N, Shepherd S, Mohammed K, Lee KA, et al
    Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
    Breast Cancer Res Treat. 2022 Aug 17. pii: 10.1007/s10549-022-06703.
    PubMed     Abstract available


  113. ZANG F, Ding X, Chen J, Hu L, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
    Breast Cancer Res Treat. 2022 Aug 16. pii: 10.1007/s10549-022-06702.
    PubMed     Abstract available


  114. LIN L, Soesan M, van Balen DEM, Beijnen JH, et al
    The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Aug 16. pii: 10.1007/s10549-022-06681.
    PubMed     Abstract available


  115. LU Y, Gehr AW, Anikpo I, Meadows RJ, et al
    Cardiotoxicity among socioeconomically marginalized breast cancer patients.
    Breast Cancer Res Treat. 2022 Aug 15. pii: 10.1007/s10549-022-06695.
    PubMed     Abstract available


  116. CHIKERMANE SG, Sharma M, Abughosh SM, Aparasu RR, et al
    Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
    Breast Cancer Res Treat. 2022 Aug 15. pii: 10.1007/s10549-022-06706.
    PubMed     Abstract available


  117. BRIGHT EE, Genung SR, Stanton AL, Arch JJ, et al
    A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2022 Aug 12. pii: 10.1007/s10549-022-06705.
    PubMed     Abstract available


  118. ENGVALL K, Green H, Fredrikson M, Lagerlund M, et al
    Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
    Breast Cancer Res Treat. 2022 Aug 9. pii: 10.1007/s10549-022-06670.
    PubMed     Abstract available


  119. TERADA M, Kondo N, Wanifuchi-Endo Y, Fujita T, et al
    Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study.
    Breast Cancer Res Treat. 2022 Aug 8. pii: 10.1007/s10549-022-06693.
    PubMed     Abstract available


  120. SAMUSIEVA A, Serga S, Klymenko S, Rybchenko L, et al
    Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    Breast Cancer Res Treat. 2022 Aug 5. pii: 10.1007/s10549-022-06692.
    PubMed     Abstract available


  121. YANG J, Guo W, Huang R, Zhou C, et al
    Letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Breast Cancer Res Treat. 2022 Aug 5. pii: 10.1007/s10549-022-06663.
    PubMed    


  122. IHENACHO U, Hamilton AS, Mack WJ, Wu AH, et al
    Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study.
    Breast Cancer Res Treat. 2022 Aug 4. pii: 10.1007/s10549-022-06675.
    PubMed     Abstract available


  123. MCALEESE CE, Butcher NJ, Minchin RF
    Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06668.
    PubMed     Abstract available


  124. MUTKA M, Virtakoivu R, Joensuu K, Hollmen M, et al
    Clever-1 positive macrophages in breast cancer.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06683.
    PubMed     Abstract available


  125. WANG X, Fan Z, Wang X, He Y, et al
    Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06686.
    PubMed     Abstract available


  126. KONISHI T, Fujiogi M, Shigemi D, Nishioka K, et al
    Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan.
    Breast Cancer Res Treat. 2022 Aug 2. pii: 10.1007/s10549-022-06659.
    PubMed     Abstract available


  127. CHEN CS, Smith EML, Stringer KA, Henry NL, et al
    Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
    Breast Cancer Res Treat. 2022;194:551-560.
    PubMed     Abstract available


  128. SELLA T, Kantor O, Weiss A, Partridge AH, et al
    The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
    Breast Cancer Res Treat. 2022;194:663-672.
    PubMed     Abstract available


  129. LIM E, Boyle F, Okera M, Loi S, et al
    An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2022 Aug 1. pii: 10.1007/s10549-022-06690.
    PubMed     Abstract available


  130. PAN K, Aragaki AK, Michael Y, Thomson CA, et al
    Long-term dietary intervention influence on physical activity in the Women's Health Initiative Dietary Modification randomized trial.
    Breast Cancer Res Treat. 2022;195:43-54.
    PubMed     Abstract available


    July 2022
  131. MCVICKER L, Cardwell CR, McIntosh SA, McMenamin UC, et al
    Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study.
    Breast Cancer Res Treat. 2022 Jul 31. pii: 10.1007/s10549-022-06674.
    PubMed     Abstract available


  132. WANG Y, Tesch ME, Lim C, Xu YH, et al
    Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06650.
    PubMed     Abstract available


  133. TANG M, O'Grady S, Crown J, Duffy MJ, et al
    MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06673.
    PubMed     Abstract available


  134. FREEDMAN RA, Revette AC, Gagnon H, Perilla-Glen A, et al
    Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06676.
    PubMed     Abstract available


  135. ANKERSMID JW, Lansink Rotgerink FK, Strobbe LJA, van Uden-Kraan CF, et al
    Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jul 30. pii: 10.1007/s10549-022-06684.
    PubMed     Abstract available


  136. KONG L, Xiong Y, Wang D, Huang L, et al
    Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06687.
    PubMed     Abstract available


  137. BAADE PD, Fowler H, Kou K, Dunn J, et al
    A prognostic survival model for women diagnosed with invasive breast cancer in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06682.
    PubMed     Abstract available


  138. SACCHINI V, Norton L
    Escalating de-escalation in breast cancer treatment.
    Breast Cancer Res Treat. 2022 Jul 28. pii: 10.1007/s10549-022-06685.
    PubMed     Abstract available


  139. KAPLAN HG, Malmgren JA, Guo B, Atwood MK, et al
    Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.
    Breast Cancer Res Treat. 2022 Jul 22. pii: 10.1007/s10549-022-06678.
    PubMed     Abstract available


  140. NGAI V, Tai JCJ, Taj S, Khanfar H, et al
    Non-invasive predictors of axillary lymph node burden in breast cancer: a single-institution retrospective analysis.
    Breast Cancer Res Treat. 2022 Jul 21. pii: 10.1007/s10549-022-06672.
    PubMed     Abstract available


  141. BRAAL CL, Westenberg JD, Buijs SM, Abrams S, et al
    Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
    Breast Cancer Res Treat. 2022 Jul 16. pii: 10.1007/s10549-022-06643.
    PubMed     Abstract available


  142. HOWARD FM, Pearson AT, Nanda R
    Clinical trials of immunotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Jul 14. pii: 10.1007/s10549-022-06665.
    PubMed     Abstract available


  143. HAMILTON E, Cortes J, Ozyilkan O, Chen SC, et al
    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Jul 12. pii: 10.1007/s10549-022-06662.
    PubMed     Abstract available


  144. NIKOLOV I, Kostev K, Kalder M
    Incidence of other cancer diagnoses in women with breast cancer: a retrospective cohort study with 42,248 women.
    Breast Cancer Res Treat. 2022 Jul 12. pii: 10.1007/s10549-022-06666.
    PubMed     Abstract available


  145. ALDRICH MB, Rasmussen JC, DeSnyder SM, Woodward WA, et al
    Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging.
    Breast Cancer Res Treat. 2022 Jul 10. pii: 10.1007/s10549-022-06667.
    PubMed     Abstract available


  146. DAVEY MG, Kerin MJ
    Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Jul 10. pii: 10.1007/s10549-022-06671.
    PubMed    


  147. WU R, Gandhi S, Tokumaru Y, Asaoka M, et al
    Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer.
    Breast Cancer Res Treat. 2022 Jul 6. pii: 10.1007/s10549-022-06661.
    PubMed     Abstract available


  148. SKARPING I, Nilsson K, Dihge L, Fridhammar A, et al
    The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer.
    Breast Cancer Res Treat. 2022 Jul 5. pii: 10.1007/s10549-022-06636.
    PubMed     Abstract available


  149. CHEN L, Chen Y, Xie Z, Luo J, et al
    Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Breast Cancer Res Treat. 2022 Jul 5. pii: 10.1007/s10549-022-06649.
    PubMed     Abstract available


  150. VIDULA N, Yau C, Rugo H
    Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
    Breast Cancer Res Treat. 2022 Jul 4. pii: 10.1007/s10549-022-06660.
    PubMed     Abstract available


  151. OKONOGI N, Karasawa K, Nitta Y, Mori Y, et al
    Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer.
    Breast Cancer Res Treat. 2022 Jul 4. pii: 10.1007/s10549-022-06644.
    PubMed     Abstract available


  152. GECZIK AM, Ferris JS, Terry MB, Andrulis IL, et al
    Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol
    Breast Cancer Res Treat. 2022 Jul 2. pii: 10.1007/s10549-022-06656.
    PubMed     Abstract available


  153. DONEY K, Leisenring W, Linden H
    Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer.
    Breast Cancer Res Treat. 2022 Jul 2. pii: 10.1007/s10549-022-06658.
    PubMed     Abstract available


  154. ELALAOUI SC, Laarabi FZ, Afif L, Lyahyai J, et al
    Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.
    Breast Cancer Res Treat. 2022;194:187-198.
    PubMed     Abstract available


  155. SHERMAN ME, de Bel T, Heckman MG, White LJ, et al
    Serum hormone levels and normal breast histology among premenopausal women.
    Breast Cancer Res Treat. 2022;194:149-158.
    PubMed     Abstract available


  156. FRIEDMAN-ELDAR O, Burke J, de Castro Silva I, Baumrucker CC, et al
    Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction.
    Breast Cancer Res Treat. 2022;194:327-335.
    PubMed     Abstract available


  157. ZHANG Y, Luo X, Chen M, Yang L, et al
    Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
    Breast Cancer Res Treat. 2022;194:279-295.
    PubMed     Abstract available


  158. MOUSA-DOUST D, Dingee CK, Chen L, Bazzarelli A, et al
    Excision of breast fibroepithelial lesions: when is it still necessary?-A 10-year review of a regional centre.
    Breast Cancer Res Treat. 2022;194:307-314.
    PubMed     Abstract available


  159. GONZALEZ A, Del Greco F, Vargas-Roig L, Brun B, et al
    PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
    Breast Cancer Res Treat. 2022;194:403-412.
    PubMed     Abstract available


  160. VICTORIA M, Marie B, Dominique R, Caroline A, et al
    Breast reconstruction and quality of life five years after cancer diagnosis: VICAN French National cohort.
    Breast Cancer Res Treat. 2022;194:449-461.
    PubMed     Abstract available


    June 2022
  161. FAUER AJ, Ganz PA, Brauer ER
    A mixed method study of medical oncologists' perceived barriers and motivators to addressing long-term effects in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jun 29. pii: 10.1007/s10549-022-06657.
    PubMed     Abstract available


  162. CHEUN JH, Lee YJ, Lee JH, Shin Y, et al
    Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Jun 28. pii: 10.1007/s10549-021-06500.
    PubMed     Abstract available


  163. BURKBAUER L, Goldbach M, Huang C, Lewandowski J, et al
    Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention.
    Breast Cancer Res Treat. 2022 Jun 25. pii: 10.1007/s10549-022-06546.
    PubMed     Abstract available


  164. FWELO P, Yusuf ZI, Adjei A, Huynh G, et al
    Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017.
    Breast Cancer Res Treat. 2022 Jun 24. pii: 10.1007/s10549-022-06653.
    PubMed     Abstract available


  165. POGGIO F, Ceppi M, Fregatti P, Lambertini M, et al
    Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and metaanalysis".
    Breast Cancer Res Treat. 2022 Jun 24. pii: 10.1007/s10549-022-06590.
    PubMed    


  166. CASTELO M, Lu J, Paszat L, Veitch Z, et al
    Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2022 Jun 22. pii: 10.1007/s10549-022-06646.
    PubMed     Abstract available


  167. HAARSMA R, van Loevezijn AA, Donswijk ML, Scholten AN, et al
    Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence.
    Breast Cancer Res Treat. 2022 Jun 21. pii: 10.1007/s10549-022-06654.
    PubMed     Abstract available


  168. ZHANG Z, Zhang H, Yu J, Xu L, et al
    miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Jun 21. pii: 10.1007/s10549-022-06642.
    PubMed     Abstract available


  169. WERNLI KJ, Smith RE, Henderson LM, Zhao W, et al
    Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density.
    Breast Cancer Res Treat. 2022 Jun 20. pii: 10.1007/s10549-022-06648.
    PubMed     Abstract available


  170. KHOURY T, Aljabab S, Yao S, Ambrosone C, et al
    Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting.
    Breast Cancer Res Treat. 2022 Jun 18. pii: 10.1007/s10549-022-06641.
    PubMed     Abstract available


  171. SELLA T, Exman P, Ren S, Freret TS, et al
    Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.
    Breast Cancer Res Treat. 2022 Jun 17. pii: 10.1007/s10549-022-06621.
    PubMed     Abstract available


  172. YADAV S, Sangaralingham L, Payne SR, Giridhar KV, et al
    Surveillance mammography after treatment for male breast cancer.
    Breast Cancer Res Treat. 2022 Jun 17. pii: 10.1007/s10549-022-06645.
    PubMed     Abstract available


  173. CORKE L, Luzhna L, Willemsma K, Illmann C, et al
    Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer.
    Breast Cancer Res Treat. 2022 Jun 15. pii: 10.1007/s10549-022-06640.
    PubMed     Abstract available


  174. JU J, Du F, Gao SL, Si YR, et al
    Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
    Breast Cancer Res Treat. 2022 Jun 14. pii: 10.1007/s10549-022-06629.
    PubMed     Abstract available


  175. WELLERDIECK NEA, Wessels P, Los M, Sonke GS, et al
    Local and systemic therapy in breast cancer patients with central nervous system metastases.
    Breast Cancer Res Treat. 2022 Jun 9. pii: 10.1007/s10549-022-06605.
    PubMed     Abstract available


  176. KONISHI T, Fujiogi M, Michihata N, Matsui H, et al
    Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study.
    Breast Cancer Res Treat. 2022 Jun 4. pii: 10.1007/s10549-022-06638.
    PubMed     Abstract available


  177. SUTHERLAND A, Huppe A, Wagner JL, Amin AL, et al
    The clinical impact of MRI on surgical planning for patients with in-breast tumor recurrence.
    Breast Cancer Res Treat. 2022;193:515-522.
    PubMed     Abstract available


  178. POMERANTZ A, Tsoref D, Grubstein A, Wadhawker S, et al
    Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
    Breast Cancer Res Treat. 2022;193:507-514.
    PubMed     Abstract available


  179. BYCHKOVSKY B, Laws A, Katlin F, Hans M, et al
    Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.
    Breast Cancer Res Treat. 2022;193:417-427.
    PubMed     Abstract available


  180. SKENDERI F, Alahmad MAM, Tahirovic E, Alahmad YM, et al
    HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
    Breast Cancer Res Treat. 2022;193:523-533.
    PubMed     Abstract available


  181. SIVADAS A, Kok VC, Ng KL
    Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.
    Breast Cancer Res Treat. 2022;193:361-379.
    PubMed     Abstract available


  182. NAKAGOMI H, Inoue M, Hirotsu Y, Amemiya K, et al
    PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery.
    Breast Cancer Res Treat. 2022;193:349-359.
    PubMed     Abstract available


  183. WEBSTER TK, Roth SC, Yu D, Baltodano PA, et al
    Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022;193:241-251.
    PubMed     Abstract available


  184. MESA-EGUIAGARAY I, Wild SH, Bird SM, Williams LJ, et al
    Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype.
    Breast Cancer Res Treat. 2022 Jun 1. pii: 10.1007/s10549-022-06632.
    PubMed     Abstract available


    May 2022
  185. OSHI M, Gandhi S, Yan L, Tokumaru Y, et al
    Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Breast Cancer Res Treat. 2022 May 31. pii: 10.1007/s10549-022-06633.
    PubMed     Abstract available


  186. PICADO O, Kwon D, Rojas K, Crystal J, et al
    Impact of genomic assays on treatment and outcomes in locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 May 30. pii: 10.1007/s10549-022-06625.
    PubMed     Abstract available


  187. SCHREIER A, Munoz-Arcos L, Alvarez A, Sparano JA, et al
    Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Breast Cancer Res Treat. 2022 May 28. pii: 10.1007/s10549-022-06574.
    PubMed     Abstract available


  188. SATO F, Sagara A, Tajima K, Miura S, et al
    COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
    Breast Cancer Res Treat. 2022 May 28. pii: 10.1007/s10549-022-06635.
    PubMed     Abstract available


  189. CASWELL-JIN JL, Shafaee MN, Xiao L, Liu M, et al
    Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06634.
    PubMed     Abstract available


  190. TOWFIGHI P, Deldar R, Haffner ZK, Aminpour N, et al
    A comparative analysis of males and females with breast cancer undergoing mastectomy using the American College of Surgeon's National Surgical Quality Improvement Project (NSQIP).
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06628.
    PubMed     Abstract available


  191. BEN DORI S, Aizic A, Zubkov A, Tsuriel S, et al
    The risk of PD-L1 expression misclassification in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 May 27. pii: 10.1007/s10549-022-06630.
    PubMed     Abstract available


  192. CULLINANE C, Brien AO, Shrestha A, Hanlon EO, et al
    The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 May 23. pii: 10.1007/s10549-022-06616.
    PubMed     Abstract available


  193. GOPINATH P, Veluswami S, Gopisetty G, Sundersingh S, et al
    Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06617.
    PubMed     Abstract available


  194. MAKARI-JUDSON G, Viskochil R, Katz D, Barham R, et al
    Insulin resistance and weight gain in women treated for early stage breast cancer.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06624.
    PubMed     Abstract available


  195. DETTWYLER SA, Thull DL, McAuliffe PF, Steiman JG, et al
    Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
    Breast Cancer Res Treat. 2022 May 21. pii: 10.1007/s10549-022-06619.
    PubMed     Abstract available


  196. EROGLU I, Sevilimedu V, Park A, King TA, et al
    Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS.
    Breast Cancer Res Treat. 2022 May 20. pii: 10.1007/s10549-021-06499.
    PubMed     Abstract available


  197. ROOT JC, Zhou X, Ahn J, Small BJ, et al
    Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-022-06623.
    PubMed     Abstract available


  198. PEREZ EA, Dang C, Lee C, Singh J, et al
    Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-021-06469.
    PubMed     Abstract available


  199. OPDAM M, van der Noort V, Kleijn M, Glas A, et al
    Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
    Breast Cancer Res Treat. 2022 May 19. pii: 10.1007/s10549-022-06618.
    PubMed     Abstract available


  200. MCGUINNESS JE, Ro V, Mutasa S, Pan S, et al
    Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.
    Breast Cancer Res Treat. 2022 May 16. pii: 10.1007/s10549-022-06614.
    PubMed     Abstract available


  201. PAPAUTSKY EL, Carlson M, Johnson SM, Montague H, et al
    Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
    Breast Cancer Res Treat. 2022 May 14. pii: 10.1007/s10549-022-06615.
    PubMed     Abstract available


  202. SAJAL IH, Chowdhury M, Wang T, Euhus D, et al
    CBCRisk-Black: a personalized contralateral breast cancer risk prediction model for black women.
    Breast Cancer Res Treat. 2022 May 13. pii: 10.1007/s10549-022-06612.
    PubMed     Abstract available


  203. PARIKH DA, Kody L, Brain S, Heditsian D, et al
    Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
    Breast Cancer Res Treat. 2022 May 11. pii: 10.1007/s10549-022-06611.
    PubMed     Abstract available


  204. O'SHAUGHNESSY J, Brufsky A, Rugo HS, Tolaney SM, et al
    Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 May 11. pii: 10.1007/s10549-022-06602.
    PubMed     Abstract available


  205. GEYER CE JR, Bandos H, Rastogi P, Jacobs SA, et al
    Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
    Breast Cancer Res Treat. 2022 May 4. pii: 10.1007/s10549-022-06613.
    PubMed    


  206. VAN BARELE M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, et al
    Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.
    Breast Cancer Res Treat. 2022 May 4. pii: 10.1007/s10549-022-06608.
    PubMed     Abstract available


  207. SWARNKAR PK, Mokbel K
    Axillary radiation alone is a suboptimal treatment for ypN + in patients with triple negative breast cancer and axillary lymph node dissection should be considered in this setting.
    Breast Cancer Res Treat. 2022 May 3. pii: 10.1007/s10549-022-06610.
    PubMed    


  208. JIA H, Zhao P, Chen Z, Wang G, et al
    Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.
    Breast Cancer Res Treat. 2022;193:111-120.
    PubMed     Abstract available


  209. CHAVDA J, Mishra A, Silodia A, Yadav SK, et al
    Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.
    Breast Cancer Res Treat. 2022;193:105-110.
    PubMed     Abstract available


  210. HALL PE, Schmid P
    Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.
    Breast Cancer Res Treat. 2022;193:21-35.
    PubMed     Abstract available


  211. SIOKA C
    Radiotherapy, chemotherapy, and heart disease.
    Breast Cancer Res Treat. 2022;193:239-240.
    PubMed    


    April 2022
  212. PATEL BK, Pepin K, Brandt KR, Mazza GL, et al
    Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE).
    Breast Cancer Res Treat. 2022 Apr 30. pii: 10.1007/s10549-022-06607.
    PubMed     Abstract available


  213. FONNESBECH HJORTH C, Damkier P, Bjerregaard Stage T, Feddersen S, et al
    Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
    Breast Cancer Res Treat. 2022 Apr 30. pii: 10.1007/s10549-022-06596.
    PubMed     Abstract available


  214. MALLORY MA, Whiting K, Park A, Gonen M, et al
    Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.
    Breast Cancer Res Treat. 2022 Apr 29. pii: 10.1007/s10549-022-06532.
    PubMed     Abstract available


  215. GIATROMANOLAKI A, Gkegka AG, Pouliliou S, Biziota E, et al
    Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06609.
    PubMed     Abstract available


  216. ANDERSON KS, Erick TK, Chen M, Daley H, et al
    The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06562.
    PubMed     Abstract available


  217. BIGHAM Z, Robles Y, Freund KM, Palmer JR, et al
    Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women's Health Study.
    Breast Cancer Res Treat. 2022 Apr 28. pii: 10.1007/s10549-022-06606.
    PubMed     Abstract available


  218. MCDONALD BC, Van Dyk K, Deardorff RL, Bailey JN, et al
    Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy.
    Breast Cancer Res Treat. 2022 Apr 27. pii: 10.1007/s10549-022-06597.
    PubMed     Abstract available


  219. LACOUTURE ME, Goldfarb SB, Markova A, Chawla SP, et al
    Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
    Breast Cancer Res Treat. 2022 Apr 26. pii: 10.1007/s10549-022-06584.
    PubMed     Abstract available


  220. LI J, Li C, Feng Z, Liu L, et al
    Effect of estradiol as a continuous variable on breast cancer survival by menopausal status: a cohort study in China.
    Breast Cancer Res Treat. 2022 Apr 25. pii: 10.1007/s10549-022-06593.
    PubMed     Abstract available


  221. HOWELL DM, Metcalfe K, Kong S, Stephen J, et al
    Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study.
    Breast Cancer Res Treat. 2022 Apr 24. pii: 10.1007/s10549-022-06576.
    PubMed     Abstract available


  222. BOMAN C, Edman Kessler L, Bergh J, Matikas A, et al
    Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.
    Breast Cancer Res Treat. 2022 Apr 24. pii: 10.1007/s10549-022-06591.
    PubMed     Abstract available


  223. HUANG HC, Smart MH, Zolekar A, Deng H, et al
    Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity.
    Breast Cancer Res Treat. 2022 Apr 23. pii: 10.1007/s10549-022-06603.
    PubMed     Abstract available


  224. PURI A, Mylavarapu C, Xu J, Patel TA, et al
    Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases.
    Breast Cancer Res Treat. 2022 Apr 23. pii: 10.1007/s10549-022-06595.
    PubMed     Abstract available


  225. DE BONIFACE J, Frisell J, Kuhn T, Wiklander-Brakenhielm I, et al
    False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2022 Apr 22. pii: 10.1007/s10549-022-06588.
    PubMed     Abstract available


  226. DREDZE LM, Friger M, Ariad S, Koretz M, et al
    Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.
    Breast Cancer Res Treat. 2022 Apr 22. pii: 10.1007/s10549-022-06598.
    PubMed     Abstract available


  227. ZHANG H, Barner JC, Moczygemba LR, Rascati KL, et al
    Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
    Breast Cancer Res Treat. 2022 Apr 21. pii: 10.1007/s10549-022-06604.
    PubMed     Abstract available


  228. VANDRAAS K, Falk RS, Bohn SKH, Kiserud C, et al
    Work ability 8 years after breast cancer: exploring the role of social support in a nation-wide survey.
    Breast Cancer Res Treat. 2022 Apr 21. pii: 10.1007/s10549-022-06599.
    PubMed     Abstract available


  229. O'DONNELL E, Shapiro Y, Comander A, Isakoff S, et al
    Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).
    Breast Cancer Res Treat. 2022 Apr 20. pii: 10.1007/s10549-022-06594.
    PubMed     Abstract available


  230. LEMIJ AA, de Glas NA, Derks MGM, Bastiaannet E, et al
    Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer.
    Breast Cancer Res Treat. 2022 Apr 19. pii: 10.1007/s10549-022-06583.
    PubMed     Abstract available


  231. ZHANG YX, Liang ZZ, Li YQ, Lin Y, et al
    Association between weight change and breast cancer prognosis.
    Breast Cancer Res Treat. 2022 Apr 18. pii: 10.1007/s10549-022-06592.
    PubMed     Abstract available


  232. CHUNG GKK, Yeo W, Cheng A, Kwok C, et al
    Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06526.
    PubMed     Abstract available


  233. KWAN ML, Cheng RK, Iribarren C, Shen H, et al
    Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06586.
    PubMed     Abstract available


  234. HAGENAARS SC, Vangangelt KMH, Van Pelt GW, Karancsi Z, et al
    Standardization of the tumor-stroma ratio scoring method for breast cancer research.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06587.
    PubMed     Abstract available


  235. LIAO YH, Lai JN, Hsu RJ, Wang TH, et al
    Breast-conserving surgery with whole breast radiation therapy has a subsequent lower mood disorder incidence rate than total mastectomy in early-stage breast cancer patients: a nationwide population-based longitudinal study.
    Breast Cancer Res Treat. 2022 Apr 16. pii: 10.1007/s10549-022-06579.
    PubMed     Abstract available


  236. KIM D, Bae SJ, Ahn SG, Jeong J, et al
    RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis.
    Breast Cancer Res Treat. 2022 Apr 15. pii: 10.1007/s10549-022-06601.
    PubMed     Abstract available


  237. DAVEY MG, Cleere EF, O'Donnell JP, Gaisor S, et al
    Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2022 Apr 15. pii: 10.1007/s10549-022-06580.
    PubMed     Abstract available


  238. FADELU TA, Erfani P, Lormil J, Damuse R, et al
    Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer.
    Breast Cancer Res Treat. 2022 Apr 14. pii: 10.1007/s10549-022-06582.
    PubMed     Abstract available


  239. PERNAS S, Tolaney SM
    Clinical trial data and emerging strategies: HER2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06575.
    PubMed     Abstract available


  240. TO NH, Nguyen HQ, Thiolat A, Liu B, et al
    Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06533.
    PubMed     Abstract available


  241. DIRIX L, Buys A, Oeyen S, Peeters D, et al
    Circulating tumor cell detection: A prospective comparison between CellSearch(R) and RareCyte(R) platforms in patients with progressive metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Apr 9. pii: 10.1007/s10549-022-06585.
    PubMed     Abstract available


  242. YE L, Runger D, Angarita SA, Hadaya J, et al
    Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.
    Breast Cancer Res Treat. 2022 Apr 7. pii: 10.1007/s10549-022-06581.
    PubMed     Abstract available


  243. KATUWAL S, Tapanainen J, Pukkala E
    Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer.
    Breast Cancer Res Treat. 2022 Apr 2. pii: 10.1007/s10549-022-06571.
    PubMed     Abstract available


  244. IYEVLEVA AG, Aleksakhina SN, Sokolenko AP, Baskina SV, et al
    Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    Breast Cancer Res Treat. 2022;192:283-291.
    PubMed     Abstract available


  245. WESTHOFF CL, Guo H, Wang Z, Hibshoosh H, et al
    The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
    Breast Cancer Res Treat. 2022;192:321-329.
    PubMed     Abstract available


  246. POLLOCK NC, Ramroop JR, Hampel H, Troester MA, et al
    Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
    Breast Cancer Res Treat. 2022;192:639-648.
    PubMed     Abstract available


  247. PALASSINI E, Mir O, Grignani G, Vincenzi B, et al
    Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.
    Breast Cancer Res Treat. 2022;192:603-610.
    PubMed     Abstract available


  248. YANG J, He T, Wu Y, Fu Z, et al
    Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers.
    Breast Cancer Res Treat. 2022;192:573-582.
    PubMed     Abstract available


  249. YAZGAN I, Chagpar A
    The effect of emotional disorders on adherence to mammography screening guidelines.
    Breast Cancer Res Treat. 2022;192:623-627.
    PubMed     Abstract available


  250. FRIDMAN I, Chan L, Thomas J, Fish LJ, et al
    A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing.
    Breast Cancer Res Treat. 2022;192:517-527.
    PubMed     Abstract available


  251. MOORE GM, Powell SN, Higginson DS, Khan AJ, et al
    Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    Breast Cancer Res Treat. 2022;192:649-653.
    PubMed     Abstract available


  252. HA SM, Kim HK, Kim Y, Noh DY, et al
    Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound.
    Breast Cancer Res Treat. 2022;192:541-552.
    PubMed     Abstract available


    March 2022
  253. FELIX GES, Guindalini RSC, Zheng Y, Walsh T, et al
    Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.
    Breast Cancer Res Treat. 2022 Mar 30. pii: 10.1007/s10549-022-06560.
    PubMed     Abstract available


  254. JORDAHL KM, Malone KE, Baglia ML, Flanagan MR, et al
    Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ.
    Breast Cancer Res Treat. 2022 Mar 27. pii: 10.1007/s10549-022-06573.
    PubMed     Abstract available


  255. LUO J, Carter SJ, Feliciano EMC, Hendryx M, et al
    Trajectories of objectively measured physical function among older breast cancer survivors in comparison with cancer-free controls.
    Breast Cancer Res Treat. 2022 Mar 26. pii: 10.1007/s10549-022-06568.
    PubMed     Abstract available


  256. MOUABBI JA, Hassan A, Lim B, Hortobagyi GN, et al
    Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
    Breast Cancer Res Treat. 2022 Mar 26. pii: 10.1007/s10549-022-06572.
    PubMed     Abstract available


  257. ASSIDICKY R, Tokat UM, Tarman IO, Saatci O, et al
    Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Mar 25. pii: 10.1007/s10549-022-06569.
    PubMed     Abstract available


  258. YANG YS, Ren YX, Liu CL, Hao S, et al
    The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
    Breast Cancer Res Treat. 2022 Mar 25. pii: 10.1007/s10549-022-06537.
    PubMed     Abstract available


  259. QI L, Sun B, Yang B, Lu S, et al
    PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Mar 24. pii: 10.1007/s10549-021-06501.
    PubMed     Abstract available


  260. WANG S, Zhang X, Ning H, Dong S, et al
    B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis.
    Breast Cancer Res Treat. 2022 Mar 21. pii: 10.1007/s10549-022-06520.
    PubMed     Abstract available


  261. TAN Q, Qin Q, Huang Z, Lian B, et al
    Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Mar 18. pii: 10.1007/s10549-022-06565.
    PubMed     Abstract available


  262. WU Y, Han Y, Li Q, Zhang P, et al
    Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Breast Cancer Res Treat. 2022 Mar 16. pii: 10.1007/s10549-022-06559.
    PubMed     Abstract available


  263. SANTIA P, Jansana A, Del Cura I, Padilla-Ruiz M, et al
    Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort.
    Breast Cancer Res Treat. 2022 Mar 15. pii: 10.1007/s10549-022-06563.
    PubMed     Abstract available


  264. ROBERSON ML, Nichols HB, Olshan AF, Wheeler SB, et al
    Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality.
    Breast Cancer Res Treat. 2022 Mar 14. pii: 10.1007/s10549-022-06564.
    PubMed     Abstract available


  265. SCOTT OW, Tin Tin S, Elwood JM, Cavadino A, et al
    Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study.
    Breast Cancer Res Treat. 2022 Mar 14. pii: 10.1007/s10549-022-06528.
    PubMed     Abstract available


  266. ANKERSMID JW, Spronk PER, Zeillemaker AM, Siesling S, et al
    Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty.
    Breast Cancer Res Treat. 2022 Mar 13. pii: 10.1007/s10549-022-06549.
    PubMed     Abstract available


  267. LIEBERMAN S, Chen-Shtoyerman R, Levi Z, Shkedi-Rafid S, et al
    Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews.
    Breast Cancer Res Treat. 2022 Mar 12. pii: 10.1007/s10549-022-06557.
    PubMed     Abstract available


  268. BOWLES EJA, Ramin C, Buist DSM, Feigelson HS, et al
    Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
    Breast Cancer Res Treat. 2022 Mar 11. pii: 10.1007/s10549-022-06561.
    PubMed     Abstract available


  269. OMOFUMA OO, Steck SE, Olshan AF, Troester MA, et al
    The association between meat and fish intake by preparation methods and breast cancer in the Carolina Breast Cancer Study (CBCS).
    Breast Cancer Res Treat. 2022 Mar 11. pii: 10.1007/s10549-022-06555.
    PubMed     Abstract available


  270. QI TH, Hian OH, Kumaran AM, Tan TJ, et al
    Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2022 Mar 9. pii: 10.1007/s10549-022-06521.
    PubMed     Abstract available


  271. YOUL P, Philpot S, Moore J, Morris M, et al
    Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia.
    Breast Cancer Res Treat. 2022 Mar 7. pii: 10.1007/s10549-022-06551.
    PubMed     Abstract available


  272. ZHU Y, Tao Z, Chen Y, Lin S, et al
    Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
    Breast Cancer Res Treat. 2022 Mar 7. pii: 10.1007/s10549-022-06514.
    PubMed     Abstract available


  273. WU R, Patel A, Tokumaru Y, Asaoka M, et al
    High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    Breast Cancer Res Treat. 2022 Mar 6. pii: 10.1007/s10549-022-06552.
    PubMed     Abstract available


  274. VAN LOEVEZIJN AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, et al
    Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    Breast Cancer Res Treat. 2022 Mar 3. pii: 10.1007/s10549-022-06545.
    PubMed     Abstract available


  275. RAGUSI MAA, van der Velden BHM, van Maaren MC, van der Wall E, et al
    Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.
    Breast Cancer Res Treat. 2022 Mar 3. pii: 10.1007/s10549-022-06550.
    PubMed     Abstract available


  276. GEYER CE JR, Bandos H, Rastogi P, Jacobs SA, et al
    Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
    Breast Cancer Res Treat. 2022 Mar 1. pii: 10.1007/s10549-021-06417.
    PubMed     Abstract available


    February 2022
  277. SHANMUGALINGAM A, Hitos K, Hegde S, Al-Mashat A, et al
    Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06548.
    PubMed     Abstract available


  278. SMEDSLAND SK, Vandraas KF, Bohn SK, Dahl AA, et al
    Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06544.
    PubMed     Abstract available


  279. GANDHI S, Brackstone M, Hong NJL, Grenier D, et al
    A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
    Breast Cancer Res Treat. 2022 Feb 28. pii: 10.1007/s10549-022-06522.
    PubMed     Abstract available


  280. CAMPONE M, De Laurentiis M, Zamagni C, Kudryavcev I, et al
    Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
    Breast Cancer Res Treat. 2022 Feb 25. pii: 10.1007/s10549-022-06543.
    PubMed     Abstract available


  281. MILLER RS, Mokiou S, Taylor A, Sun P, et al
    Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ(R) study.
    Breast Cancer Res Treat. 2022 Feb 22. pii: 10.1007/s10549-022-06541.
    PubMed     Abstract available


  282. NIE W, Ding H, Zou X
    Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis".
    Breast Cancer Res Treat. 2022 Feb 17. pii: 10.1007/s10549-022-06542.
    PubMed    


  283. BOGACH J, Cordeiro E, Reel E, Cil TD, et al
    Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2022 Feb 13. pii: 10.1007/s10549-022-06540.
    PubMed     Abstract available


  284. ALI A, Xie Z, Stanko L, De Leo E, et al
    Endocrine adherence in male versus female breast cancer: a seer-medicare review.
    Breast Cancer Res Treat. 2022 Feb 10. pii: 10.1007/s10549-022-06536.
    PubMed     Abstract available


  285. HICKISH T, Mehta A, Liu MC, Huang CS, et al
    Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
    Breast Cancer Res Treat. 2022 Feb 9. pii: 10.1007/s10549-021-06449.
    PubMed     Abstract available


  286. JAGSI R, Mason G, Overmoyer BA, Woodward WA, et al
    Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
    Breast Cancer Res Treat. 2022 Feb 8. pii: 10.1007/s10549-022-06534.
    PubMed    


  287. DIRIX LY, Oeyen S, Buys A, Liegois V, et al
    Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer.
    Breast Cancer Res Treat. 2022 Feb 8. pii: 10.1007/s10549-021-06484.
    PubMed     Abstract available


  288. JACOBS CF, Soesan M, Sonke GS
    Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???
    Breast Cancer Res Treat. 2022 Feb 7. pii: 10.1007/s10549-021-06505.
    PubMed     Abstract available


  289. KARIRI Y, Toss MS, Alsaleem M, Elsharawy KA, et al
    Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
    Breast Cancer Res Treat. 2022 Feb 6. pii: 10.1007/s10549-022-06531.
    PubMed     Abstract available


  290. MORGANTI S, Marra A, Crimini E, D'Amico P, et al
    Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Breast Cancer Res Treat. 2022 Feb 6. pii: 10.1007/s10549-022-06535.
    PubMed     Abstract available


  291. OKINES A, Irfan T, Asare B, Mohammed K, et al
    Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
    Breast Cancer Res Treat. 2022 Feb 4. pii: 10.1007/s10549-021-06432.
    PubMed     Abstract available


  292. LIN PH, Chen SC, Tseng LM, Chang KJ, et al
    Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    Breast Cancer Res Treat. 2022 Feb 3. pii: 10.1007/s10549-021-06446.
    PubMed     Abstract available


  293. GANZ PA, Bandos H, Geyer CE Jr, Robidoux A, et al
    Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
    Breast Cancer Res Treat. 2022 Feb 3. pii: 10.1007/s10549-021-06475.
    PubMed     Abstract available


  294. BYUN HK, Kim JS, Chang JS, Cho Y, et al
    Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05).
    Breast Cancer Res Treat. 2022 Feb 2. pii: 10.1007/s10549-021-06507.
    PubMed     Abstract available


  295. VO JB, Ramin C, Barac A, Berrington de Gonzalez A, et al
    Trends in heart disease mortality among breast cancer survivors in the US, 1975-2017.
    Breast Cancer Res Treat. 2022 Feb 2. pii: 10.1007/s10549-022-06515.
    PubMed     Abstract available


  296. BAEK SY, Kim J, Chung IY, Ko BS, et al
    Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study.
    Breast Cancer Res Treat. 2022;192:143-152.
    PubMed     Abstract available


  297. RODIN D, Sutradhar R, Nofech-Mozes S, Gu S, et al
    Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.
    Breast Cancer Res Treat. 2022;192:223-233.
    PubMed     Abstract available


  298. RILEY D, Chrischilles EA, Lizarraga IM, Charlton M, et al
    Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000-2015.
    Breast Cancer Res Treat. 2022;192:211-222.
    PubMed     Abstract available


  299. SEAH DS, Tayob N, Leone JP, Hu J, et al
    Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings.
    Breast Cancer Res Treat. 2022;192:201-210.
    PubMed     Abstract available


  300. KIM N, Kim H, Park W, Choi DH, et al
    Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching.
    Breast Cancer Res Treat. 2022;192:101-112.
    PubMed     Abstract available


  301. GUMUSAY O, Callan J, Rugo HS
    Immunotherapy toxicity: identification and management.
    Breast Cancer Res Treat. 2022;192:1-17.
    PubMed     Abstract available


  302. LO GULLO R, Cloutier Lambert C, Lin O, Jochelson MS, et al
    Yield of flow cytometry in addition to cytology for lymph node sampling in patients with incidental axillary adenopathy without a concurrent diagnosis of primary breast malignancy.
    Breast Cancer Res Treat. 2022;191:677-683.
    PubMed     Abstract available


  303. GOHAR J, Do WL, Miller-Kleinhenz J, Conneely K, et al
    Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities.
    Breast Cancer Res Treat. 2022;191:653-663.
    PubMed     Abstract available


    January 2022
  304. VERHOEFF TJ, Holloway AF, Dickinson JL
    A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer.
    Breast Cancer Res Treat. 2022 Jan 31. pii: 10.1007/s10549-021-06496.
    PubMed     Abstract available


  305. NGUYEN TTA, Postlewait LM, Zhang C, Meisel JL, et al
    Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 27. pii: 10.1007/s10549-022-06530.
    PubMed     Abstract available


  306. LI C, Li R, Hu X, Zhou G, et al
    Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.
    Breast Cancer Res Treat. 2022 Jan 27. pii: 10.1007/s10549-021-06433.
    PubMed     Abstract available


  307. ZHAO Y, Peng H, Liang L, Li Y, et al
    Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
    Breast Cancer Res Treat. 2022 Jan 26. pii: 10.1007/s10549-021-06490.
    PubMed     Abstract available


  308. REID S, Spalluto LB, Lang K, Weidner A, et al
    An overview of genetic services delivery for hereditary breast cancer.
    Breast Cancer Res Treat. 2022 Jan 26. pii: 10.1007/s10549-021-06478.
    PubMed     Abstract available


  309. FRANZOI MA, Lambertini M, Ceppi M, Bruzzone M, et al
    Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
    Breast Cancer Res Treat. 2022 Jan 25. pii: 10.1007/s10549-022-06525.
    PubMed     Abstract available


  310. WILLIAMS AD, Buckley M, Ciocca RM, Sabol JL, et al
    Racial and socioeconomic disparities in breast cancer diagnosis and mortality in Pennsylvania.
    Breast Cancer Res Treat. 2022 Jan 22. pii: 10.1007/s10549-021-06492.
    PubMed     Abstract available


  311. CONDORELLI M, Sens M, Goldrat O, Delbaere A, et al
    A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06489.
    PubMed     Abstract available


  312. MARTINEZ JA, Wertheim BC, Roe DJ, Chalasani P, et al
    Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06485.
    PubMed     Abstract available


  313. SUELMANN BBM, Bakhuis CFJ, van Dooijeweert C, Verloop J, et al
    Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06471.
    PubMed     Abstract available


  314. LIANG Y, Besch-Williford C, Hyder SM
    The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.
    Breast Cancer Res Treat. 2022 Jan 17. pii: 10.1007/s10549-021-06487.
    PubMed     Abstract available


  315. JONES GS, Hoadley KA, Benefield H, Olsson LT, et al
    Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.
    Breast Cancer Res Treat. 2022 Jan 16. pii: 10.1007/s10549-021-06497.
    PubMed     Abstract available


  316. PAVANELLI AC, Mangone FR, Yoganathan P, Bessa SA, et al
    Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
    Breast Cancer Res Treat. 2022 Jan 15. pii: 10.1007/s10549-021-06452.
    PubMed     Abstract available


  317. CHOI SB, Park JM, Ahn JH, Go J, et al
    Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06519.
    PubMed     Abstract available


  318. ALTERIO D, La Rocca E, Volpe S, Camarda AM, et al
    Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06516.
    PubMed     Abstract available


  319. MEEGDES M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, et al
    The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06472.
    PubMed     Abstract available


  320. FASANO GA, Bayard S, Chen Y, Varella L, et al
    Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06481.
    PubMed     Abstract available


  321. ANGARITA FA, Oshi M, Yamada A, Yan L, et al
    Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06482.
    PubMed     Abstract available


  322. YOO TK, Kang J, Lee A, Chae BJ, et al
    A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06437.
    PubMed     Abstract available


  323. VERDONE CG, Bayron JA, Chang C, Wang CE, et al
    A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA.
    Breast Cancer Res Treat. 2022 Jan 11. pii: 10.1007/s10549-021-06460.
    PubMed     Abstract available


  324. PATEL R, Li Z, Zimmerman BS, Fink MY, et al
    Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06504.
    PubMed     Abstract available


  325. DONZELLA SM, Lind KE, Skiba MB, Farland LV, et al
    The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health Initiative.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06486.
    PubMed     Abstract available


  326. VOHRA SN, Reeder-Hayes KE, Nichols HB, Emerson MA, et al
    Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-022-06511.
    PubMed     Abstract available


  327. SARMA M, Perimbeti S, Nasir S, Attwood K, et al
    Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06506.
    PubMed     Abstract available


  328. CHEUNG YM, Cromwell GE, Tolaney SM, Min L, et al
    Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06476.
    PubMed     Abstract available


  329. LEE J, Chang Y, Kim Y, Park B, et al
    Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-022-06513.
    PubMed     Abstract available


  330. ANDERSON RA, Kelsey TW, Perdrix A, Olympios N, et al
    Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-021-06508.
    PubMed     Abstract available


  331. CONLEY CC, McIntyre M, Pensak NA, Lynce F, et al
    Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-022-06518.
    PubMed     Abstract available


  332. SAGHATCHIAN M, Abehsera M, Yamgnane A, Geyl C, et al
    Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06445.
    PubMed     Abstract available


  333. KIRAC UTKU I, Safer U
    Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer-results from the ABLE feasibility trial.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06502.
    PubMed    


  334. BLUMING AZ
    Safety of systemic hormone replacement therapy in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06479.
    PubMed    


  335. ZHENG C, Chagpar AB
    Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-022-06510.
    PubMed     Abstract available


  336. TANG A, Neeman E, Vuong B, Arasu VA, et al
    Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-021-06468.
    PubMed     Abstract available


  337. BRINGUIER M, Carton M, Levy C, Patsouris A, et al
    Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.
    Breast Cancer Res Treat. 2022 Jan 5. pii: 10.1007/s10549-021-06467.
    PubMed     Abstract available


  338. COOLBRANDT A, Vancoille K, Dejaeger E, Peeters H, et al
    Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06477.
    PubMed     Abstract available


  339. FALLOWFIELD LJ, Farewell D, Jones H, May S, et al
    IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06491.
    PubMed     Abstract available


  340. FAN Y, Xie G, Wang Z, Wang Y, et al
    PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
    Breast Cancer Res Treat. 2022 Jan 3. pii: 10.1007/s10549-021-06463.
    PubMed     Abstract available


  341. JAGSI R, Mason G, Overmoyer BA, Woodward WA, et al
    Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
    Breast Cancer Res Treat. 2022 Jan 1. pii: 10.1007/s10549-021-06434.
    PubMed     Abstract available


  342. HU Y, Burkard ME
    Classes of therapeutics to amplify the immune response.
    Breast Cancer Res Treat. 2022;191:277-289.
    PubMed     Abstract available


  343. PAWLOSKI KR, Gonen M, Wen HY, Tadros AB, et al
    Supervised machine learning model to predict oncotype DX risk category in patients over age 50.
    Breast Cancer Res Treat. 2022;191:423-430.
    PubMed     Abstract available


  344. KHAYEKA-WANDABWA C, Zhao J, Pathak JL, Wu H, et al
    Upregulation of estrogen receptor alpha (ERalpha) expression in transgenic mice expressing human CYP4Z1.
    Breast Cancer Res Treat. 2022;191:319-326.
    PubMed     Abstract available


  345. LEWIS PHILLIPS G, Guo J, Kiefer JR, Proctor W, et al
    Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.
    Breast Cancer Res Treat. 2022;191:303-317.
    PubMed     Abstract available


  346. HUANG L, Wang R, Xie K, Zhang J, et al
    A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Breast Cancer Res Treat. 2022;191:51-61.
    PubMed     Abstract available


  347. BAKER JL, Haji F, Kusske AM, Fischer CP, et al
    SAVI SCOUT(R) localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Breast Cancer Res Treat. 2022;191:107-114.
    PubMed     Abstract available


  348. SIEGEL A, Bremer RC, Klein WMP, Savage SA, et al
    Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    Breast Cancer Res Treat. 2022;191:159-167.
    PubMed     Abstract available


  349. POULSEN L, Kaur M, Jacobsen AL, Bjarnesen MP, et al
    Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
    Breast Cancer Res Treat. 2022;191:87-96.
    PubMed     Abstract available


  350. SHIINO S, Ball G, Syed BM, Kurozumi S, et al
    Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
    Breast Cancer Res Treat. 2022;191:1-14.
    PubMed     Abstract available


  351. DOLEN UC, Law J, Tenenbaum MM, Myckatyn TM, et al
    Breast reconstruction is a viable option for older patients.
    Breast Cancer Res Treat. 2022;191:77-86.
    PubMed     Abstract available


    December 2021
  352. MORASSO C, Ricciardi A, Sproviero D, Truffi M, et al
    Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA).
    Breast Cancer Res Treat. 2021 Dec 21. pii: 10.1007/s10549-021-06474.
    PubMed     Abstract available


  353. YADAV K, Lim J, Choo J, Ow SGW, et al
    Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2021 Dec 20. pii: 10.1007/s10549-021-06470.
    PubMed     Abstract available


  354. SCHAEFGEN B, Funk A, Sinn HP, Bruckner T, et al
    Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
    Breast Cancer Res Treat. 2021 Dec 8. pii: 10.1007/s10549-021-06466.
    PubMed     Abstract available


  355. TURNER N, Dent RA, O'Shaughnessy J, Kim SB, et al
    Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
    Breast Cancer Res Treat. 2021 Dec 3. pii: 10.1007/s10549-021-06450.
    PubMed     Abstract available


  356. JAZIEH K, Baidoun F, Torrejon N, Merjaneh Z, et al
    Studying the association between breast cancer and renal cell carcinoma.
    Breast Cancer Res Treat. 2021 Dec 2. pii: 10.1007/s10549-021-06465.
    PubMed     Abstract available


  357. MORGAT C, Brouste V, Chastel A, Velasco V, et al
    Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.
    Breast Cancer Res Treat. 2021;190:403-413.
    PubMed     Abstract available


  358. NEIRICH L, Yahiaoui-Doktor M, Lammert J, Basrai M, et al
    Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
    Breast Cancer Res Treat. 2021;190:463-475.
    PubMed     Abstract available


  359. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, van Stam LE, et al
    The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06458.
    PubMed     Abstract available


  360. DINH P, Graham JD, Elder EN, Kabir M, et al
    Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06456.
    PubMed     Abstract available


    November 2021
  361. METCALFE KA, Eisen A, Wright F, Poll A, et al
    Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06457.
    PubMed     Abstract available


  362. DISIS ML, Cecil DL
    Breast cancer vaccines for treatment and prevention.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06459.
    PubMed     Abstract available


  363. COE F, Misra V, McCabe Y, Adderley H, et al
    Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06438.
    PubMed     Abstract available


  364. DREHER N, Matthys M, Hadeler E, Shieh Y, et al
    A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06451.
    PubMed     Abstract available


  365. BRANDS-APPELDOORN ATPM, Thomma RCM, Janssen L, Maaskant-Braat AJG, et al
    Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06461.
    PubMed     Abstract available


  366. LI Y, Zheng X, Tu D, Ingle JN, et al
    Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.
    Breast Cancer Res Treat. 2021 Nov 26. pii: 10.1007/s10549-021-06448.
    PubMed     Abstract available


  367. HARBORG S, Ahern TP, Feldt M, Rosendahl AH, et al
    Circulating lipids and breast cancer prognosis in the Malmo diet and cancer study.
    Breast Cancer Res Treat. 2021 Nov 25. pii: 10.1007/s10549-021-06462.
    PubMed     Abstract available


  368. SMALL BJ, Lange M, Zhai W, Ahn J, et al
    Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06455.
    PubMed     Abstract available


  369. HONKANEN TJ, Luukkainen MEK, Tikkanen A, Karihtala P, et al
    Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06447.
    PubMed     Abstract available


  370. BARNI S, Cognetti F, Petrelli F
    Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06464.
    PubMed     Abstract available


  371. ROTHSCHILD HT, Abel MK, Patterson A, Goodman K, et al
    Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06453.
    PubMed     Abstract available


  372. SILVER J, Goldenberg A, Moore A
    Dietary supplement use and documentation in a breast cancer survivorship clinic.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06454.
    PubMed     Abstract available


  373. ZUO K, Yuan X, Liang X, Sun X, et al
    qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Nov 19. pii: 10.1007/s10549-021-06442.
    PubMed     Abstract available


  374. ROSIER L, Wang Y, Lee JH, Daily K, et al
    Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
    Breast Cancer Res Treat. 2021 Nov 17. pii: 10.1007/s10549-021-06440.
    PubMed     Abstract available


  375. JANK P, Lindner JL, Lehmann A, Pfitzner BM, et al
    Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
    Breast Cancer Res Treat. 2021 Nov 16. pii: 10.1007/s10549-021-06415.
    PubMed     Abstract available


  376. WU ZY, Han J, Kim HJ, Lee JW, et al
    Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06350.
    PubMed     Abstract available


  377. BOSE M, Benada J, Thatte JV, Kinalis S, et al
    A catalog of curated breast cancer genes.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06441.
    PubMed     Abstract available


  378. KLINGER M, Losurdo A, Lisa AVE, Morenghi E, et al
    Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06444.
    PubMed     Abstract available


  379. REN M, Orozco A, Shao K, Albanez A, et al
    Correction to: Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06373.
    PubMed    


  380. NYROP KA, Damone EM, Deal AM, Wheeler SB, et al
    Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Nov 5. pii: 10.1007/s10549-021-06439.
    PubMed     Abstract available


  381. POGGIO F, Del Mastro L, Bruzzone M, Ceppi M, et al
    Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06436.
    PubMed     Abstract available


  382. WILSON BE, Gorrini C, Cescon DW
    Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06431.
    PubMed     Abstract available


  383. CHO Y, Chang Y, Jung HS, Kim CW, et al
    Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2021;190:343-353.
    PubMed     Abstract available


  384. AMITAI Y, Menes TS, Scaranelo A, Fleming R, et al
    The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI.
    Breast Cancer Res Treat. 2021;190:317-327.
    PubMed     Abstract available


  385. ARNONE AA, Cline JM, Soto-Pantoja DR, Cook KL, et al
    Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-alpha activity on breast metabolic signaling.
    Breast Cancer Res Treat. 2021;190:53-67.
    PubMed     Abstract available


  386. AL-KAWAZ A, Ali R, Toss MS, Miligy IM, et al
    The frequency and clinical significance of DNA polymerase beta (POLbeta) expression in breast ductal carcinoma in situ (DCIS).
    Breast Cancer Res Treat. 2021;190:39-51.
    PubMed     Abstract available


  387. TAPIA E, Villa-Guillen DE, Chalasani P, Centuori S, et al
    A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
    Breast Cancer Res Treat. 2021;190:69-78.
    PubMed     Abstract available


  388. LAZZARO C
    Lazzaro responds to Pouwels et al.
    Breast Cancer Res Treat. 2021;190:1.
    PubMed    


    October 2021
  389. WU ZY, Kim HJ, Lee J, Chung IY, et al
    Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06428.
    PubMed     Abstract available


  390. WAN C, Caston NE, Ingram SA, Rocque GB, et al
    Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06422.
    PubMed     Abstract available


  391. TORRES ETR, Emens LA
    Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06423.
    PubMed     Abstract available


  392. HUPPERT LA, Mariotti V, Chien AJ, Soliman HH, et al
    Emerging immunotherapeutic strategies for the treatment of breast cancer.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06406.
    PubMed     Abstract available


  393. HO AY, Tabrizi S, Dunn SA, McArthur HL, et al
    Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06408.
    PubMed     Abstract available


  394. JENKINS JA, Marmor S, Hui JYC, Beckwith H, et al
    The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06429.
    PubMed     Abstract available


  395. SCHREIBER AR, Kagihara J, Eguchi M, Kabos P, et al
    Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Breast Cancer Res Treat. 2021 Oct 27. pii: 10.1007/s10549-021-06424.
    PubMed     Abstract available


  396. LUCANUS AJ, Thike AA, Tan XF, Lee KW, et al
    KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence.
    Breast Cancer Res Treat. 2021 Oct 26. pii: 10.1007/s10549-021-06426.
    PubMed     Abstract available


  397. GOLD EB, Crawford SL, Leung K, Greendale G, et al
    Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN.
    Breast Cancer Res Treat. 2021 Oct 25. pii: 10.1007/s10549-021-06425.
    PubMed     Abstract available


  398. CRESCENZI R, Donahue PMC, Garza M, Lee CA, et al
    Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06419.
    PubMed     Abstract available


  399. CORBAUX P, Lardy-Cleaud A, Alexandre M, Fontanilles M, et al
    Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06382.
    PubMed     Abstract available


  400. ONEGA T, Zhu W, Kerlikowske K, Miglioretti DL, et al
    Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield.
    Breast Cancer Res Treat. 2021 Oct 22. pii: 10.1007/s10549-021-06418.
    PubMed     Abstract available


  401. CHIC N, Braso-Maristany F, Prat A
    Biomarkers of immunotherapy response in breast cancer beyond PD-L1.
    Breast Cancer Res Treat. 2021 Oct 21. pii: 10.1007/s10549-021-06421.
    PubMed     Abstract available


  402. MILLS MN, Potluri TK, Kawahara Y, Fahey M, et al
    The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs.
    Breast Cancer Res Treat. 2021 Oct 20. pii: 10.1007/s10549-021-06420.
    PubMed     Abstract available


  403. CAO L, Shenk R, Stabellini N, Miller ME, et al
    Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis.
    Breast Cancer Res Treat. 2021 Oct 16. pii: 10.1007/s10549-021-06411.
    PubMed     Abstract available


  404. LORONA NC, Malone KE, Li CI
    Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis.
    Breast Cancer Res Treat. 2021 Oct 15. pii: 10.1007/s10549-021-06311.
    PubMed     Abstract available


  405. ZHENG F, Du F, Wang W, Wang Y, et al
    Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    Breast Cancer Res Treat. 2021 Oct 14. pii: 10.1007/s10549-021-06401.
    PubMed     Abstract available


  406. CHAMSEDDINE RS, Wang C, Yin K, Wang J, et al
    Penetrance of male breast cancer susceptibility genes: a systematic review.
    Breast Cancer Res Treat. 2021 Oct 13. pii: 10.1007/s10549-021-06413.
    PubMed     Abstract available


  407. MERZENICH H, Baaken D, Schmidt M, Bekes I, et al
    Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa).
    Breast Cancer Res Treat. 2021 Oct 9. pii: 10.1007/s10549-021-06412.
    PubMed     Abstract available


  408. HERNANDO-CALVO A, Cescon DW, Bedard PL
    Novel classes of immunotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06405.
    PubMed     Abstract available


  409. DE LAURENTIIS M, Borstnar S, Campone M, Warner E, et al
    Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06374.
    PubMed    


  410. VARGAS A, Holub K, Biete A
    Omitting axillary dissection: could we offer a more tailored management to elderly patients with breast cancer?
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06404.
    PubMed     Abstract available


  411. BIANCO N, Milano M, Pagan E, Oriecuia C, et al
    Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06407.
    PubMed     Abstract available


  412. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Correction to: Breast cancer, diabetes mellitus and glucagonlike peptide1 receptor toward exploring their possible associations.
    Breast Cancer Res Treat. 2021 Oct 4. pii: 10.1007/s10549-021-06380.
    PubMed    


  413. SAVAS P, Salgado R, Loi S
    Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers.
    Breast Cancer Res Treat. 2021;189:599-606.
    PubMed     Abstract available


  414. CHIPIDZA FE, Mushonga M, Kanda C, Chibonda S, et al
    Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe.
    Breast Cancer Res Treat. 2021;189:701-709.
    PubMed     Abstract available


  415. ESSERMAN L, Eklund M, Veer LV, Shieh Y, et al
    The WISDOM study: a new approach to screening can and should be tested.
    Breast Cancer Res Treat. 2021;189:593-598.
    PubMed    


    September 2021
  416. SOLIMAN O, Lowery A, Kerin M
    Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06403.
    PubMed    


  417. HAQUE R, Chlebowski RT, Chen L
    Sleep medication use and risk of fractures in breast cancer survivors.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06392.
    PubMed     Abstract available


  418. ROCQUE GB, Caston NE, Franks JA, Williams CP, et al
    Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06381.
    PubMed     Abstract available


  419. THOREN L, Eriksson M, Lindh JD, Czene K, et al
    Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 27. pii: 10.1007/s10549-021-06386.
    PubMed     Abstract available


  420. TEINTURIER R, Abou Ziki R, Kassem L, Luo Y, et al
    Reduced menin expression leads to decreased ERalpha expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06339.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: